Publication: Biologic agents in psoriasis
Date
Authors
Başkan, Emel Bülbül
Authors
Advisor
Language
Type
Publisher:
Vakıf Gureba Eğitim ve Araştırma Hastanesi Kliniği
Journal Title
Journal ISSN
Volume Title
Abstract
Psoriasis is a chronic, inflammatory disease affecting 1-3% of population. Advances in the pathogenesis of psoriasis and biotechnology have led to the development of targeted therapy named biologic agents. in this review, general information on biologic drugs are presented and literature on four biologic agents available in our country for moderate to severe plaque psoriasis has been summarized. Mechanisms of action, indications and dosage, results of clinical studies and safety profiles of each biologic agent are discussed.
Description
Source:
Keywords:
Keywords
Dermatology, Adalimumab, Biologics, Efalizumab, Etanercept, Infliximab, Psoriasis, Chronic plaque psoriasis, Randomized controlled-trial, Patient-reported outcomes, Long-term, treatment, Phase-III, Double-blind, Efalizumab therapy, Rheumatoid-arthritis, Open-label, Infliximab monotherapy
Citation
Başkan, E. B. (2008). "Biologic agents in psoriasis". Turkderm Deri Hastaliklari ve Frengi Arsivi, 40(Supplement 2), 42-50